U.S. Markets closed

Biocartis Group NV (BCART.BR)

Brussels - Brussels Delayed Price. Currency in EUR
Add to watchlist
4.9100+0.1450 (+3.04%)
At close: 5:35PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.7650
Open4.7900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.7500 - 4.9150
52 Week Range2.7500 - 6.8800
Volume169,550
Avg. Volume121,930
Market Cap276.836M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-1.1660
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.02
  • Press news Biocartis Group NV - Regulated Information : Disclosure of a transparency notification
    GlobeNewswire

    Press news Biocartis Group NV - Regulated Information : Disclosure of a transparency notification

    PRESS RELEASE - REGULATED INFORMATION24 November 2020, 07:00 CETDisclosure of a transparency notificationMechelen, Belgium, 24 November 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the ‘Belgian Transparency Act’), that on 19 November 2020 it received a transparency notification dated 19 November 2020 (the ‘Notification’), indicating that on that date the shareholding of Debiopharm Innovation Fund S.A. decreased below the 3% notification threshold. Debiopharm Innovation Fund S.A. now holds 2.95% of the voting rights in Biocartis.The Notification contains the following information: * Reason for the Notification: Acquisition or disposal of voting securities or voting rights, and downward crossing of the lowest threshold.   * Notification by: A parent undertaking or a controlling person.   * Person subject to the notification requirement: Debiopharm Innovation Fund S.A., Chemin Messidor 5-7, 1006 Lausanne, Switzerland; Après-Demain S.A. (formerly Après-Demain Holding S.A.), Chemin Messidor 5-7, 1006 Lausanne, Switzerland; Thierry Mauvernay, Chemin du Praz-Buchilly 113, 1000 Lausanne 25, Switzerland.   * Transaction date: 19 November 2020.   * Threshold that is crossed: 3%.   * Denominator: 56,382,088.   * Details of the Notification: Debiopharm Innovation Fund S.A. now holds 1,662,963 voting securities.   * Chain of controlled undertakings through which the holding is effectively being held: Debiopharm Innovation Fund S.A. is controlled by Après-Demain S.A. (formerly Après-Demain Holding S.A.), which is controlled by Mr. Thierry Mauvernay.For further information, reference is made to the Notification which is available here on the Biocartis website.Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (‘FSMA’) is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.\--- END --- More information: Renate Degrave Head of Corporate Communications & Investor Relations Biocartis e-mail   rdegrave@biocartis.com tel         +32 15 631 729 mobile   +32 471 53 60 64 About BiocartisBiocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for SARS-CoV-2 and sepsis. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.Forward-looking statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Attachment * 20201119 DPIF tr-1be-ENG_FINAL

  • Press news Biocartis Group NV: Biocartis Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay Showing Very Low Failure Rates and Excellent Concordance with Reference Methods
    GlobeNewswire

    Press news Biocartis Group NV: Biocartis Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay Showing Very Low Failure Rates and Excellent Concordance with Reference Methods

    PRESS RELEASE17 November 2020, 07:00 CET Biocartis Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay Showing Very Low Failure Rates and Excellent Concordance with Reference Methods Mechelen, Belgium, 17 November 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of a global multi-center real world study1 with its Idylla™ MSI Assay. This multi-center study is the largest so far for Biocartis and demonstrates excellent performance of the Idylla™ MSI Assay2 with a very low failure rate.In this real-world global study, 44 clinical centers performed Idylla™ MSI testing on 1,301 archived colorectal cancer FFPE3 tissue sections. Idylla™ results were compared against routine diagnostic testing in those sites, demonstrating excellent concordance with immunohistochemistry (96%4) and routine molecular methods (98%)5. Additionally, the failure rate of the Idylla™ MSI Assay was very low (0.23%; 3/1301), underlining the robustness of the Idylla™ MSI Assay.Microsatellite instability (MSI) is the result of inactivation of the body’s so-called DNA mismatch repair (MMR) system. Consequently, errors that normally spontaneously occur during DNA replication are no longer corrected, contributing to tumor growth and evolution. Microsatellite instability (MSI) is present in 15–20% of primary colorectal cancers and MSI status is assessed to detect Lynch syndrome6, guide adjuvant chemotherapy, determine prognosis, and use as a companion test for checkpoint blockade inhibitors. Traditionally, MSI status is determined by immunohistochemistry7 or molecular diagnostic testing methods. Although it is recommended for all colorectal, endometrial and several other cancers8, MSI testing remains underused today since current methods are highly complex.The fully automated Idylla™ MSI Test9 (CE-IVD) was developed to overcome these drawbacks and provides information on the MSI status10 within approximately 150 minutes from just one slice of FFPE tumor tissue, without the need for a reference sample.Herman Verrelst, Chief Executive Officer of Biocartis, commented: “We are pleased with this very large and strong data set for our Idylla™ MSI Test. MSI is increasingly used as a biomarker that guides therapies or determines prognosis for a growing number of cancers. We believe that the unique aspects of the Idylla™ MSI Test, which clearly shows great advantages over current MSI testing methods on the market, could enable a broader penetration of MSI testing. Very large, global studies such as these really contribute to show the unique features of our Idylla™ MSI Test.”The study is published in Virchows Archive1 and is available online here. The Idylla™ MSI Test received its CE-marking on 28 February 2019. For more info, go to the Biocartis website.\--- END --- More information: Renate Degrave Head of Corporate Communications & Investor Relations Biocartis e-mail   rdegrave@biocartis.com tel         +32 15 631 729 mobile   +32 471 53 60 64 About BiocartisBiocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for SARS-CoV-2 and sepsis. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_. Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.Forward-looking statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. * * * 1 A. Velasco et al., Multi-center real-world comparison of the fully automated Idylla™ microsatellite instability assay with routine molecular methods and immunohistochemistry on formalin-fixed paraffin-embedded tissue of colorectal cancer, Virchows Archiv https://doi.org/10.1007/s00428-020-02962-x, November 20202 RUO = Research Use Only, not for use in diagnostic procedures3 FFPE = formalin-fixed, paraffin-embedded4 17/37 discordant samples were found to be concordant with the Idylla™ result when a third method was used5 Third-method analysis found concordance with the Idylla™ result for 8/16 discordant samples6 Which is one of the most common hereditary cancer syndromes and results in a significantly increased risk of developing colorectal or other cancers such as endometrial or gastric cancer. MSI testing with CRC patients is important to see if the CRC is hereditary (meaning the patient has Lynch syndrome), because in such case there is a risk that their family members could also have an increased chance of developing colorectal or other tumors. Source: https://fightcolorectalcancer.org/fight/diagnosis/what-is-msi-and-mss/ and https://www.asco.org/about-asco/press-center/news-releases/genomic-study-finds-lynch-syndrome-common-among-people-msi, last consulted on 12 November 20207 Immunohistochemistry is a laboratory method that uses antibodies to check for certain antigens (markers) in a sample of tissue. It’s used to help diagnose diseases, such as cancer. It may also be used to help tell the difference between different types of cancer. Source: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immunohistochemistry, last consulted on 12 November 20208 Source: ASCO guidelines, www.asco.org/endorsements/HereditaryCRC, last consulted on 12 November 20209 The Idylla™ MSI Test is intended for the qualitative detection of a novel panel of seven monomorphic homopolymer biomarkers for identification of colorectal cancers (CRC) with microsatellite instability (MSI)10 i.e. Microsatellite Instability-High (MSI-H) or Microsatellite Stable (MSS)

  • GlobeNewswire

    Press news Biocartis Group NV: Biocartis Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

    PRESS RELEASE: 16 November 2020, 17:40 CETBiocartis Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting Mechelen, Belgium, 16 November 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of ten performance studies of its fully-automated molecular diagnostics  Idylla™ platform at the annual meeting of the ‘Association for Molecular Pathology’ (AMP), a leading molecular diagnostics conference taking place virtually this year between 16-20 November 2020. The respective Idylla™ studies once again highlight the strengths of the Idylla™ platform and assays1 in terms of performance, ease of use and turnaround time, as well as Idylla™’s capacity to overcome the obstacles of working with small amounts of sample, which represents a major challenge for many current molecular testing methods in a variety of different cancer types. Furthermore, three studies discuss new Biocartis assays in the area of infectious disease: the Idylla™ SARS-CoV-2 Assay and the SeptiCyte® RAPID on Idylla™.The published oncology studies include the Idylla™ MSI, EGFR, ctEGFR, KRAS and ctKRAS Mutation Assays: * The Memorial Sloan Kettering Cancer Center (New York, US) study2 evaluated the performance of the Idylla™ MSI Assay across different tumor types (pan-cancer) including endometrial, colorectal, prostate, small bowel and breast cancer. Data presented showed equivalency to Immunohistochemistry (IHC)3 and a greater sensitivity compared to MSK-IMPACT™, a Next Generation Sequencing (NGS) test, where the Idylla™ MSI Assay provided definitive results for numerous indeterminate cases. * The University of Alabama at Birmingham (Birmingham, Alabama, US) study4 showed 100% agreement between the Idylla™ MSI Assay and IHC using prostatectomy specimens and describes the Idylla™ MSI Assay as a reliable option for MSI testing in high-grade prostate cancer. * The Dartmouth-Hitchcock Medical Center (New Hampshire, US) study5 showed the feasibility of the Idylla™ MSI Assay to identify Lynch Syndrome6 using colorectal adenomas. * Two Massachusetts General Hospital (Boston, Massachusetts, US) studies showed how rapid testing with Idylla™ can complement comprehensive PCR/NGS7 workflows, based on testing with the Idylla™ EGFR Mutation Assay and the Idylla™ ctKRAS Mutation Assay. Both studies show a reduction of the turnaround time with Idylla™ testing by approximately 50% or more, next to its ease of use and usefulness to provide for results when NGS fails8. * Another University of Alabama at Birmingham (Birmingham, Alabama, US) study9 evaluated the performance of the Idylla™ KRAS Mutation Assay using de-stained cytology smears of lung non-small cell carcinoma (NSCLC) cases as an alternative source to rescue limited quantity samples. Comparison with previous NGS results showed 100% concordance.  * The Dartmouth-Hitchcock Medical Center (New Hampshire, US) study10 evaluated the Idylla™ ctEGFR Mutation Assay on samples with DNA concentrations insufficient for NGS. Results showed a majority of samples successfully tested at a concentration of less than 40 ng DNA.In addition, three studies discuss new Biocartis products in the area of infectious disease: * The Dartmouth-Hitchcock Medical Center (New Hampshire, US) study11 evaluated the Idylla™ SARS-CoV-2 Assay showing 100% concordance with their reference method.  * Biocartis’ partner Immunexpress will present two abstracts12 demonstrating that the new SeptiCyte® RAPID on Idylla™ correlates strongly with Immunexpress’ existing SeptiCyte® LAB test, is reproducible, and can be used not only to differentiate patients with bacterial and viral, but also candida sepsis13 from clinical controls.Abstracts of the studies are published in the November 2020 issue of the Journal of Molecular Diagnostics.Herman Verrelst, Chief Executive Officer of Biocartis, commented: “We are proud of so many Idylla™ studies and abstracts being published at the renowned AMP conference this year. Having strong Idylla™ data published by leading US key opinion leaders, this time also on our newest infectious disease assays, continues to be a key driver in the further market adoption of the Idylla™ platform. We are pleased to once again see strong performance of our Idylla™ assays1 compared to other methods such as IHC and NGS, combined with Idylla™’s rapid results reporting, ease of use and minimal sample requirements, even for samples that failed on other testing methods.” Biocartis will also host a corporate workshop led by Dr. Maria E. Arcila, MD, Director of the Diagnostic Molecular Pathology Laboratory at Memorial Sloan Kettering Cancer Center (New York, US). Biocartis’ partner Immunexpress will host a recorded workshop on the SeptiCyte® RAPID on Idylla™ led by Roy Davis, M.D., Ph.D., MHA, Chief Medical Officer at Immunexpress. For more info, go to the Biocartis events website.\--- END --- More information: Renate Degrave Head of Corporate Communications & Investor Relations Biocartis e-mail   rdegrave@biocartis.com tel         +32 15 631 729 mobile   +32 471 53 60 64 About BiocartisBiocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for SARS-CoV-2 and sepsis. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_. Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.Forward-looking statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. * * * 1 All studies were performed with Idylla™ RUO assays, research use only, not for use in diagnostic procedures2 ST41. Rapid Assessment of Microsatellite Instability across a Spectrum of Tumor Types Using the Idylla System, Momeni-Boroujeni1, M. Arcila2, D. Ferguson2, U. Patel2, R. Chan2, J. Barbee2, A. Zehir2, J. Hechtman2, M. Ladanyi2, K. Nafa2 1Brigham and Women's Hospital, Boston, MA; 2Memorial Sloan Kettering Cancer Center, New York, NY3 Immunohistochemistry is a laboratory method that uses antibodies to check for certain antigens (markers) in a sample of tissue. It’s used to help diagnose diseases, such as cancer. It may also be used to help tell the difference between different types of cancer. Source: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immunohistochemistry, last consulted on 12 November 20204 ST06. Assessment of Microsatellite Instability on a Multi-Racial Cohort of High Grade Prostate Cancer Using Idylla MSI Test, M. Rodriguez Pena, S. Harada, A. Mackinnon, G. Netto, University of Alabama at Birmingham, Birmingham, AL5 ST60. Microsatellite Instability Testing for Lynch Syndrome Screening in Colorectal Adenomas, Javanbakht, L. Tafe, G. Tsongalis, E. Bradley, K. Godwin, D. Green, W. Keegan, B. Ren Dartmouth-Hitchcock Medical Center, Lebanon, NH6 Lynch Syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is a type of inherited cancer syndrome associated with a genetic predisposition to different cancer types. This means people with Lynch syndrome have a higher risk of certain types of cancer. Source: cancer.net, last consulted in 12 November 20207 PCR = Polymerase Chain Reaction. NGS = Next Generation Sequencing8 The first study (ST40. Rapid qPCR Testing in the NGS Era Enables Same-Day Resulting of EGFR Mutant NSCLC, H. Marble, N. Georgantas, J. Lennerz Massachusetts General Hospital, Boston, MA) shows how replacing their current rapid PCR/EC assay with the Idylla™ EGFR Mutation Assay provides more comprehensive mutation coverage and can reduce the overall turnaround time by ~50%. Idylla™ delivers results on the same day as tumor sampling in most cases and enables targeted EGFR profiling of even scant tumor samples. Their second study (ST24. Benefits of Rapid Genotyping of KRAS Mutations versus NGS in Pancreatic Cyst Fluids; H. Marble, A. Farahani, N. Georgantas, J. Lennerz Massachusetts General Hospital, Boston, MA) demonstrates how rapid KRAS genotyping of pancreatic cysts with the Idylla™ ctKRAS Mutation Assay can be used to complement NGS-based profiling of pancreatic cancer. Idylla™ enables sample to result in 2.5 hours versus 10 to 14 days for NGS; is easy to use; and can provide results when NGS fails9 ST08. De-stained Cytology Smears Can Be Used for Detection of KRAS Mutations Using the Biocartis Idylla PCR-Based Molecular Diagnostic Assay, Q. Wei, S. Harada, I. Eltoum, G. DeFrank, A. Mackinnon, University of Alabama at Birmingham, Birmingham, AL10 TT25. Evaluation of the Biocartis Idylla ctEGFR Mutation Assay on Samples with DNA Concentrations Insufficient for Next-Generation Sequencing (NGS), W. Keegan, L. Tafe, E. Bradley, D. Green, G. Tsongalis Dartmouth-Hitchcock Medical Center, Lebanon, NH11 ID42. Evaluation of a Sample-to-Answer Cartridge-Based SARS-CoV-2 Assay, J. Lefferts, D. Green, G. Tsongalis, Dartmouth-Hitchcock Medical Center, Lebanon, NH12 ID02. Comparison of a Cartridge-Based Host Gene Expression Test to a Manual Method for Use in the Diagnosis of Sepsis, S. Cermelli1, K. Heath2, I. Keuleers3, G. Knox2, B. Lopansri4, J. McCleave5,M. Oethinger2, P. Sillekens3, W. Sinclair5, S. Thompson2, T. Vanhoey3 1IMMUNEXPRESS, Seattle, WA; 2 Providence Oregon Regional Laboratory, Portland, OR; 3Biocartis, Mechelen, Belgium; 4Intermountain Healthcare, Murray, UT; 5Intermountain Healthcare Laboratory Services, Murray, UT.; ID10. In silico Performance of a Rapid Sepsis Test in Patients with Candidemia, SSD. Sampson1, J. Butler2, H. Peters Sengers2; 1Immunexpress, Seattle, WA; 2 Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands13 In addition to bacteria, fungi—mainly Candida albicans and other Candida spp. —can cause sepsis and this entity has increased over the last decades, now causing significant impact and health care-associated costs. In addition, fungal sepsis is associated with a higher mortality than bacterial sepsis. Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601378/, last consulted on 12 November 2020